Negi Anil K, Browning Andrew C, Vernon Stephen A
Ophthalmology Department, Eye and ENT Centre, Queen's Medical Centre University Hospital, Nottingham, United Kingdom.
J Cataract Refract Surg. 2006 Mar;32(3):468-74. doi: 10.1016/j.jcrs.2005.12.102.
To evaluate the safety and efficacy of a single perioperative sub-Tenon's injection of triamcinolone following cataract surgery and its effect on the incidence of early pseudophakic cystoid macular edema (CME).
Ophthalmology Department, Queen's Medical Centre University Hospital, Nottingham. United Kingdom.
This prospective randomized controlled trial included 54 eyes (54 patients) having routine cataract surgery. Twenty-seven eyes received the conventional postoperative care with steroid drops (drops group), whereas the other 27 were given a perioperative sub-Tenon's injection of triamcinolone (injection group); 10 of these received 20 mg, and the remaining 17 eyes had 30 mg triamcinolone. All patients were evaluated preoperatively and at days 1, 8, 30, and 90. The outcome measures evaluated were logMAR best corrected visual acuity (BCVA), anterior chamber flare (Kowa-500 flare meter), intraocular pressure, and slitlamp biomicroscopy. Oral fluorescein angiograms were performed at 30 and 90 days to detect angiographic CME.
The mean logMAR BCVA improved from a baseline of 0.38 +/- 0.38 (SD) and 0.44 +/- 0.26 to 0.02 +/- 0.14 and 0.0 +/- 0.07 at 90 days in the steroid drops and injection groups, respectively. (P = .59). The mean flare increased from a baseline of 8.9 +/- 3.2 photons/ms and 8.3 +/- 3.7 photons/ms in the steroid drops and injection groups, respectively, to a maximum of +/-14.1 photons/ms and 25.8 +/- 7.5 photons/ms at day 8. Mean flare decreased to 15.8 +/- 9.7 photons/ms and 13.8 +/- 10.1 photons/ms at 30 days (P = .48, difference between groups) and 10.4 +/- 3.6 photons/ms and 9.8 +/- 3.1 photons/ms at 90 days, respectively, in the 2 groups. Subanalysis revealed lowest peak flare (17.9 +/- 7.9 photons/ms) at 8 days in the group that received 30 mg triamcinolone.
A single sub-Tenon's injection of 30 mg triamcinolone seem to be safe and effective as a route of steroid delivery after uneventful phacoemulsification surgery. Larger numbers in patients at high risk are required to assess its effectiveness in reducing the risk for pseudophakic CME.
评估白内障手术后单次围手术期球周注射曲安奈德的安全性和有效性,及其对早期人工晶状体性黄斑囊样水肿(CME)发生率的影响。
英国诺丁汉女王医疗中心大学医院眼科。
这项前瞻性随机对照试验纳入了54只眼(54例患者)接受常规白内障手术。27只眼接受常规术后类固醇滴眼液护理(滴眼液组),而另外27只眼接受围手术期球周注射曲安奈德(注射组);其中10只眼接受20mg,其余17只眼接受30mg曲安奈德。所有患者在术前以及术后第1天、第8天、第30天和第90天进行评估。评估的结果指标包括logMAR最佳矫正视力(BCVA)、前房闪光(Kowa-500闪光仪)、眼压和裂隙灯生物显微镜检查。在第30天和第90天进行口服荧光素血管造影以检测血管造影性CME。
类固醇滴眼液组和注射组的平均logMAR BCVA分别从基线时的0.38±0.38(标准差)和0.44±0.26改善至90天时的0.02±0.14和0.0±0.07。(P = 0.59)。类固醇滴眼液组和注射组的平均闪光分别从基线时的8.9±3.2光子/毫秒和8.3±3.7光子/毫秒在第8天增加至最大值±14.1光子/毫秒和25.8±7.5光子/毫秒。在第30天时,平均闪光分别降至15.8±9.7光子/毫秒和13.8±10.1光子/毫秒(两组间差异,P = 0.48),在第90天时,两组分别降至10.4±3.6光子/毫秒和9.8±3.1光子/毫秒。亚组分析显示,接受30mg曲安奈德的组在第8天时闪光峰值最低(17.9±7.9光子/毫秒)。
对于顺利完成超声乳化手术后的类固醇给药途径,单次球周注射30mg曲安奈德似乎是安全有效的。需要更多高危患者来评估其在降低人工晶状体性CME风险方面的有效性。